Non insulin-dependent diabetes mellitus (type 2) secondary failure. Metformin-glibenclamide treatment

International Journal of Immunopathology and Pharmacology

Volumn 14, Issue 1, 2001, Pages 31-43

  Guagnano, M T ^a   Pace Palitti, V ^a   Manigrasso, M R ^a   Merlitti, D ^a   Soto Parra, H M ^a   Sensi, S ^a  

^a Policlinico Colle dell'Ara   (Italy)

Author keywords

Glibenclamide; Metformin; Non insulin dependent diabetes mellitus; Secondary failure

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BUFORMIN; GLIBENCLAMIDE; INSULIN; METFORMIN; PHENFORMIN; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TOLBUTAMIDE;

BLOOD GLUCOSE MONITORING; DRUG EFFECT; DRUG MECHANISM; HUMAN; INSULIN RELEASE; INSULIN TREATMENT; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT FAILURE;

EID: 0035057541     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200101400106     Document Type: Short Survey

References (155)

1. Early clinical evaluation of a new oral non-sulphonylurea hypoglycaemic agent
2. Studies in the metabolic changes induced by administration of guanidine bases. Influence of injected guanidine hydrochloride upon blood sugar content
3. Clinical report of a new hypoglycaemic agent
4. Resorption und verteilung im gewebe und ausscheidung won 1-Butyl-biguanid (14C)-hydrochlorid
5. Metabolic effects of the biguanides and possible mechanism of action
6. Mode of action of blood glucose lowering biguanides: Clinical aspects
7. Current views on the mode of action of blood glucose lowering biguanides
8. Effects of biguanides on fatty acid and glucose oxidation in muscle
9. Biguanides and intestinal absorptive function
10. Biguanides
11. The mechanism of the acute hypoglycaemic action of phenformin (DBI)
12. Biguanides: A review of history, pharmacodynamics and theraphy
13. Biguanides and NIDDM
14. Phenformin acidosis
15. Irreversible lactic acidosis phenformin therapy
16. Phenformin-induced lactic acidosis in diabetic patients
17. Lactic acidosis in biguanide treated diabetics. A review of 330 cases
18. Phenformin and lactic acidosis
19. A Study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes
20. Phenformin: Removal from general market
21. Inhibition of hepatic gluconeogenesis in Guinea pig by Phenformin
22. The effect of Phenformin on pheriperal glucose utilization and insulin action in obesity and diabetes mellitus
23. Butilbiguanide effects on metabolism of blood glucose and lactic acid in skeletal muscle of diabetic patients
24. Einflus des butyl-biguanids auf den milchsaure-stoffwechsel im skelettmuskel des diabetikers
25. Metformin kinetics in healthy subjects and in patients with diabetes mellitus
26. The status of metformin in Canada
27. Metformin reduces insulin requirements in type 1 (insulin-dependent) diabetes
28. Metformin improved insulin resistance in type 1 insulin-dependent diabetic patients
29. Improvement in insulin action is an important part of the antidiabetic effect of metformin
30. Mechanism of metformin action in non-insulin-dependent diabetes
31. Metformin revisited: Its actions and indications for use
32. Metformin: A review of its pharmacological properties and therapeutic use
33. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes
34. Comparison of the vitro effect of biguanides and sulphonylureas on insulin binding to its receptors in target cells
35. Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes
36. Insulin receptor binding to monocytes insulin secretion and glucose tolerance following metformin treatment: Results of a double-blind crossover study in type II diabetics
37. Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II patients
38. Mechanism of action of metformin: Insulin receptor and post-receptor effects in vitro and in vivo
39. Effects of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes
40. Improvement with metformin in insulin internalization and processing in monocytes from NIDDM patients
41. Cellular mechanisms of action of metformin
42. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin induced translocation of glucose transported from intracellular pool to plasma membrane in rat adipocyte
43. Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle
44. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells
45. Hypolipidemic effects of metformin in hyperprebetalipoproteinemia
46. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
47. Metformin induced changes in serum lipids lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus
48. Placebo controlled trial effects of guar gum and metformin on fasting blood glucose and serum lipids in obese type 2 diabetic patients
49. Treatment of diabetes in patients with severe obesity
50. Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: An in situ microdialysis study
51. Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients
52. Effects of Metformin on collagen glycation and diastolic dysfunction in diabetic myocardium
53. Cardiovascular effects of oral hypoglycaemic drugs
54. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: The BIGPRO 1.2 trial
55. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome
56. How to manage metabolic complications of HIV therapy: What to do while we wait for answers
57. Metformin and lactic acidosis
58. Role of metformin accumulation in metformin-associated lactic acidosis
59. Metformin-induced lactic acidosis in the presence of acute renal failure
60. Metformin and the sulphonylureas: The comparative risk
61. Metformin associated lactic acidosis in Sweden 1977-1991
62. Metformin in management of pregnant insulin-dependent diabetics
63. Oral "antidiabetic" compounds in pregnancy
64. Current pathophysiological and clinical aspects of the mode of action of blood glucose lowering sulphonamides
65. Accidents hypoglycemiques graves par un sulfamidothiazol
66. Relations entre la structure moleculaire et l'activate hypoglycèmiante des aminosulphamides hypoglycemiantes
67. Relation de mècanisme de l'action hypoglycèmiante du p-aminobenzènesulfamidoisopropylthiodiazol
68. Etude physiologique et pharmacodynamique de certains derives sulphamides hypoglycemiants
69. Mode of action of blood glucose lowering sulphonamides. Other extrapancreatic effects
70. Failure of sulphonylureas to suppress plasma glucagon in man
71. Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas
72. Studies of pancreatic alpha cell function in normal and diabetic subjects
73. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes
74. Controversy over study of diabetes drugs continues for nearly a decade
75. The University Group Diabetes Program: A statistician look at the mortality results
76. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)
77. The crux of the UGDP: Spurious results and biologically inappropriate data analysis
78. Policy statement: The UGDP controversy
79. Sulphonylureas: Why which, and how?
80. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Multi-centre study
81. Reduction in HbA13c with basal insulin supplement, sulphonylurea or biguanide therapy
82. Study design, progress and performance
83. Oral hypoglycaemic agents
84. Assessment of the need for continued oral therapy in diabetes
85. Extrapancreatic effects of hypoglycaemic sulphonylureas: Still a controversial issue
86. Plasma glucagon and clinical control for maturity-onset type diabetes: Effects of diet, placebo and glipizide
87. The effect of glibenclamide treatment on the insulin and glucagon responses to orale glucose and galactose in maturity onset diabetics
88. Sulfonylureas in insulin-dependent (type I) diabetes: Evidence for an extrapancreatic effect in vivo
89. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: An overview
90. Characterization of the sulphonylurea receptor on beta cell membranes
91. Sulphonylureas do not affect insulin binding or glycaemic control in insulin-dependent diabetics
92. Sulphonylurea therapy fails to diminish insulin resistance in type 1 diabetic subjects
93. Acute effects of glyburide on insulin sensitivity in type I diabetic patients
94. Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glybenclamide
95. + channel in insulin-secreting cells
96. Characterization of the sulphonylurea receptor on beta cell membranes
97. Prolonged sulphonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabete mellitus: Evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues
98. Trial of sulphonylurea in combination with insulin in the therapy of diabetes type I and II: Evidence against a primary extrapancreatic receptor effect
99. Mechanism of improvement in glucose metabolism after chronic glyburide therapy
100. Effect of sulphonylureas on hepatic fatty acid oxidation
101. Potentiation of the hepatic action of insulin by chlorpropamide
102. Comparative tolerability of sulphonylureas in diabetes mellitus
103. In vitro effects of a sulphonylurea on insulin action in adipocytes: Potentiation of insulin-stimulated hexose transport
104. Sulphonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimeperide and glibenclamide
105. Insulinotropic effect of new glibenclamide isosters
106. Effects of K (ATP) channel blockade by glibenclamide on the warm-up phenomenon
107. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulphonylureas (glibenclamide)
108. Inhibitory effects of glibenclamide on the contraction of human arterial conduits used in coronary artery bypass surgery
109. Cyclic AMP phosphodiesterase in diabetes: Effect of glyburide
110. Clinical practice recommendation
111. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years
112. Secondary failure to treatment with oral antidiabetics agents in non-insulin-dependent diabetes
113. Tolbutamide after ten years
114. Tolbutamide after ten years
115. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulphonylurea therapy
116. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy
117. Is combination sulphonylurea and insulin therapy useful in NIDDM patients? A meta-analysis
118. Combined insulin and sulphonylurea therapy in non-insulin-dependent diabetes with secondary failure to oral drugs; a one year follow-up
119. Sulphonylurea failure in type 2 diabetes: Treatment with a basal insulin supplement
120. When to use insulin in the maturity onset diabetic?
121. Insulin for the non-insulin dependent?
122. Effects of the combination of insulin and glibenclamide in type II (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents
123. Insulin versus insulin plus sulphonylureas in type 2 diabetic patients with secondary failure to sulphonylureas
124. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: A 1-year follow-up
125. Glyburide decreases insulin requirement, increases betacell response to mixed meal, and does not affect insulin sensitivity. Effects of short and long-term combined treatment in secondary failure to sulphonylurea
126. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles
127. Metabolic effects of combined sulphonylurea and metformin therapy in maturity onset diabetics
128. Combined sulphonylurea-biguanide therapy or non-insulin-dependent diabetics. Metabolic effects of glibenclamide and metformin or phenformin in newly diagnosed obese patients
129. New anti diabetic drugs
130. Combined metformin/gliburide treatment NIDDM patients not optimally responding to maximum dose sulphonylurea: Results of a multicenter trial
131. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus
132. Evaluation of the efficay of metformin-glibenclamide treatment in overweight non-insulin dependent diabetics
133. Combining sulphonylureas and other oral agents
134. Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients
135. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients
136. A randomized trial of efficacy of early addition of metformin in sulphonylurea-treated type 2 diabetes
137. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
138. A 6-year, randomized, controlled trial comparing sulphonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
139. Efficacy of metformin in the treatment of NIDDM. Meta-analysis
140. Metformin and glibenclamide: Comparative risks
141. Does holiday hypoglycaemia exists?
142. Circadian rhythm of immunoreactive insulin under glycaemic stimulus
143. Circadian rhythm of insulin induced hypoglycaemia in man
144. Diurnal variation in response to tolbutamide
145. Circadian variation in insulin response to tolbutamide and related hormonal levels in fasting healthy subjects
146. Characterization of the molecular mode of action of the sulphonylurea, glimeperide, at the beta cells
147. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients
148. Effect of repaglinide addition to metformin monotherapy on patients with type 2 diabetes
149. Effect of troglitazone on b-cell function, insulin sensitivity and glycaemic control in subjects with type 2 diabetes mellitus
150. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
151. Thiazolidinediones: An update
152. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs